Lv31
340 积分 2022-02-18 加入
A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy
1小时前
已关闭
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
Out with the old, in with the new: what changes in the 9th edition of the TNM classification for lung cancer?
4个月前
已完结
[Advances in diagnosis and treatment and whole process management of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer]
6个月前
已关闭
Brigatinib activates inflammasomes: Implication for immune-related adverse events
6个月前
已完结
皖公网安备34019202002308
